The Microbiome and Outcomes After Allogeneic Transplant

Video
Conference|American Society of Hematology Annual Meeting & Exposition (ASH)

In this interview we discuss advances in the relationship between the microbiome and outcomes after allogeneic transplant, including graft-vs-host disease and relapse.

In this video, Robert Jenq, MD, of the Memorial Sloan Kettering Cancer Center, discusses advances in the relationship between the microbiome and outcomes after allogeneic transplant, including graft-vs-host disease and relapse.

Dr. Jenq spoke at an education session on improving outcomes of bone marrow transplants in patients with hematologic malignancies at the 58th Annual Meeting of the American Society of Hematology, held December 3–6 in San Diego, California.

Recent Videos
It can cause thrombocytopenia and diarrhea, which are generally manageable and not too big a deal.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
Related Content
We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.

Understanding Predictive Markers Drives Ruxolitinib Usage in Myelofibrosis

Tim Cortese
September 12th 2025
Article

According to Francesca Palandri, MD, PhD, ruxolitinib will have a less significant effect in patients with myelofibrosis who have a cytopenic phenotype.

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 15th 2025
Podcast

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Impact of Posttransplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 Years and Older: An Update from BMT CTN 1703

Impact of Posttransplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 Years and Older: An Update from BMT CTN 1703

American Society for Transplantation and Cellular Therapy
September 3rd 2025
Article

Researchers from the BMT CTN reported that posttransplant cyclophosphamide-based GVHD prophylaxis significantly improves outcomes for adults aged 70 years and older undergoing allo-HCT.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

The overall pain experience among adult and pediatric patients with severe sickle cell disease significantly improved after exa-cel infusion.

Exa-cel Exhibits Meaningful HRQoL Benefit in Severe Sickle Cell Disease

Roman Fabbricatore
August 31st 2025
Article

The overall pain experience among adult and pediatric patients with severe sickle cell disease significantly improved after exa-cel infusion.

Rusfertide Earns FDA BTD for Erythrocytosis in Polycythemia Vera

Rusfertide Earns FDA BTD for Erythrocytosis in Polycythemia Vera

Ariana Pelosci
August 25th 2025
Article

Results from the phase 3 VERIFY trial of rusfertide for erythrocytosis in patients with polycythemia vera led to the FDA decision.